2-amino-5-phosphonovalerate has been researched along with Parkinson Disease, Secondary in 2 studies
2-Amino-5-phosphonovalerate: The D-enantiomer is a potent and specific antagonist of NMDA glutamate receptors (RECEPTORS, N-METHYL-D-ASPARTATE). The L form is inactive at NMDA receptors but may affect the AP4 (2-amino-4-phosphonobutyrate; APB) excitatory amino acid receptors.
Parkinson Disease, Secondary: Conditions which feature clinical manifestations resembling primary Parkinson disease that are caused by a known or suspected condition. Examples include parkinsonism caused by vascular injury, drugs, trauma, toxin exposure, neoplasms, infections and degenerative or hereditary conditions. Clinical features may include bradykinesia, rigidity, parkinsonian gait, and masked facies. In general, tremor is less prominent in secondary parkinsonism than in the primary form. (From Joynt, Clinical Neurology, 1998, Ch38, pp39-42)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Calabresi, P | 1 |
| Saiardi, A | 1 |
| Pisani, A | 1 |
| Baik, JH | 1 |
| Centonze, D | 1 |
| Mercuri, NB | 1 |
| Bernardi, G | 1 |
| Borrelli, E | 1 |
| Svensson, A | 1 |
| Carlsson, ML | 1 |
2 other studies available for 2-amino-5-phosphonovalerate and Parkinson Disease, Secondary
| Article | Year |
|---|---|
Abnormal synaptic plasticity in the striatum of mice lacking dopamine D2 receptors.
Topics: 2-Amino-5-phosphonovalerate; 6-Cyano-7-nitroquinoxaline-2,3-dione; Animals; Cerebral Cortex; Corpus | 1997 |
Injection of the competitive NMDA receptor antagonist AP-5 into the nucleus accumbens of monoamine-depleted mice induces pronounced locomotor stimulation.
Topics: 2-Amino-5-phosphonovalerate; Animals; Biogenic Monoamines; Clonidine; Disease Models, Animal; Drug S | 1992 |